secwatch.observer — SEC 8-K summary
======================================

Issuer:     CVRx, Inc. (CVRX)
CIK:        0001235912
Form:       8-K
Filed at:   2024-01-31T23:59:59+00:00
Accession:  0001104659-24-008555
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CVRx appoints Kevin Hykes as President and CEO effective Feb 12, 2024; Yared retires
--------------------------------------------------------------------------------

- Hykes, a board member since Dec 2022, succeeds Nadim Yared who retires Feb 11, 2024 and will consult through Dec 2024 at $550/hr.
- Hykes receives $640K base salary, 75% target cash incentive, $150K sign-on bonus, and option for 360K shares vesting over 4 years.
- Option grant is an inducement award under Nasdaq Rule 5635(c)(4) with exercise price equal to closing price on Feb 12, 2024.
- Hykes brings 30 years med device experience; previously CEO of Augmedics, Bardy Diagnostics, Relievant Medsystems, and Cameron Health.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1235912/000110465924008555/0001104659-24-008555-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1235912/000110465924008555/tm244504d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-008555

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer